On or around 04/10/2019 (Ongoing date of last review)
Filing Date: April 10, 2019
According to the Complaint, GTx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions.
This action stems from a proposed transaction announced on March 7, 2019 (the “Proposed Transaction”), pursuant to which GTx, Inc. will merge with Oncternal Therapeutics, Inc.
On April 8, 2019, Defendants filed a Form S-4 Registration Statement (the “Registration Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.
Company & Securities Information
Defendant: GTx, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: GTXI
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.